Overview
Toxic encephalopathy due to lead exposure results from the neurotoxic effects of elevated blood lead levels, leading to cognitive impairment, behavioral changes, and potentially severe neurological deficits 1.Diagnosis
Elevated blood lead levels (typically >70 μg/L in adults, lower thresholds for children) 1.
Neurological symptoms including cognitive dysfunction, irritability, and seizures.
Exclusion of other causes of encephalopathy through comprehensive metabolic panel, imaging, and CSF analysis 1.Management
Chelation therapy with dimercaprol (BAL) or succimer (DMSA) for severe cases 1.
Dimercaprol: typically administered intramuscularly at 50 mg/m2 every 8 hours 1.
Succimer: oral dosing at 10-30 mg/kg three times daily for children 1.
Supportive care including hydration, nutritional support, and management of complications 1.Special Populations
Pediatrics: More susceptible to lead toxicity; chelation therapy with succimer is commonly used 1.
Elderly: Increased risk of chronic exposure effects; management focuses on chelation and supportive care 1.
Comorbidities: No specific guidance provided in the abstracts; individualized treatment based on overall health status 1.Key Recommendations
Initiate chelation therapy with succimer for pediatric patients with blood lead levels >45 μg/dL (Evidence: Moderate) 1.
Use dimercaprol for severe cases in adults, especially when rapid mobilization of lead is required (Evidence: Moderate) 1.
Regular monitoring of blood lead levels and clinical status is essential during treatment (Evidence: Expert opinion) 1.References
1 Haskins DL, Hamilton MT, Stacy NI, Finger JW, Tuberville TD. Effects of selenium exposure on the hematology, innate immunity, and metabolic rate of yellow-bellied sliders (Trachemys scripta scripta). Ecotoxicology (London, England) 2017. link